- Previous Close
0.0870 - Open
0.0870 - Bid 0.0850 x --
- Ask 0.0910 x --
- Day's Range
0.0870 - 0.0870 - 52 Week Range
0.0450 - 0.1100 - Volume
15,839 - Avg. Volume
175,878 - Market Cap (intraday)
19.538M - Beta (5Y Monthly) 1.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.
www.firebrickpharma.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: FRE.AX
View MorePerformance Overview: FRE.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FRE.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FRE.AX
View MoreValuation Measures
Market Cap
19.54M
Enterprise Value
18.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-152.38%
Return on Assets (ttm)
-52.89%
Return on Equity (ttm)
-111.71%
Revenue (ttm)
1.13M
Net Income Avi to Common (ttm)
-1.72M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
911.2k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.08M